<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922348</url>
  </required_header>
  <id_info>
    <org_study_id>823553</org_study_id>
    <nct_id>NCT02922348</nct_id>
  </id_info>
  <brief_title>Hormone Replacement for Premature Ovarian Insufficiency</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to establish feasibility/acceptability of a pilot randomized trial
      comparing hormone replacement therapy (HRT) and combined oral contraceptives (COCs) in women
      with premature ovarian insufficiency to estimate differences in quality of life (QOL) and
      serum hormone assays and markers of bone turnover/cardiovascular risk. At baseline, QOL
      survey will be administered and serum testing performed. Patients then randomized to HRT or
      COCs. Repeat testing will be performed after 3 and 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature ovarian insufficiency (POI) is a term used to describe when a woman's ovaries stop
      working normally before the natural age of menopause. Early sequelae of POI include vasomotor
      symptoms, vaginal dryness, mood swings and insomnia due to estrogen deficiency. Long-term
      sequelae such as loss of bone mineral density and cardiovascular risk carry are considerable
      concerns. While exogenous estrogen replacement is recommended for the POI patient population,
      the optimal regimen for replacement is not clear. One approach to hormone replacement therapy
      (HRT) is to mimic physiologic ovarian function through full replacement doses of estrogen
      (either orally or transdermally) to reach the typical serum estradiol levels of a
      menstruating woman (approximately 104 pg/mL per day) with cyclic progestin therapy for
      endometrial protection. Another approach uses daily combined estrogen-progestin oral
      contraceptives (COCs), for ease of administration and increased social acceptability. To
      date, few studies have been performed comparing the two treatment methods in terms of quality
      of life measures (vasomotor symptoms, bleeding profile, sexual dysfunction, satisfaction with
      contraception), endocrine function, bone turnover or cardiovascular risk in POI patients. In
      this proposal, the investigators intend to establish feasibility and acceptability of a pilot
      randomized controlled trial comparing traditional HRT with COCs in women with POI and to
      evaluate differences in quality of life measures, hormone assays, bone turnover and
      cardiovascular risk between treatment arms. The investigators hypothesize that acceptability
      and feasibility of the pilot trial will be high and that differences will be detected for all
      measured variables between treatment arms. Demonstration of feasibility and acceptability of
      this pilot would allow for the pursuit of a larger trial and identification of a superior
      treatment regimen would have a meaningful impact on the short and long-term care of this
      patient population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>1 year</time_frame>
    <description>Patient willingness to participate and be randomized</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasomotor symptoms - Greene Climacteric Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Greene Climacteric Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotor symptoms - Menopausal Vasomotor Symptoms (MVS) survey</measure>
    <time_frame>1 year</time_frame>
    <description>Menopausal Vasomotor Symptoms (MVS) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding profile - Bleeding questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Bleeding questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding profile - Menstrual diary</measure>
    <time_frame>1 year</time_frame>
    <description>Menstrual diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual dysfunction - Female Sexual Function Index (FSFI)</measure>
    <time_frame>1 year</time_frame>
    <description>Female Sexual Function Index (FSFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction as Contraceptive Method</measure>
    <time_frame>1 year</time_frame>
    <description>Birth Control Satisfaction Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - FSH (mIU/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>FSH (mIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Estradiol (pg/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>Estradiol (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Sex-hormone binding globulin (nmol/L)</measure>
    <time_frame>1 year</time_frame>
    <description>Sex-hormone binding globulin (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Total testosterone (ng/dL)</measure>
    <time_frame>1 year</time_frame>
    <description>Total testosterone (ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Free testosterone (ng/dL)</measure>
    <time_frame>1 year</time_frame>
    <description>Free testosterone (ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Anti-mullerian hormone (pmol/l)</measure>
    <time_frame>1 year</time_frame>
    <description>Anti-mullerian hormone (pmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Dehydroepiandrosterone Sulfate (ng/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>Dehydroepiandrosterone Sulfate (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone Assays - Thyroid stimulating hormone (U/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>Thyroid stimulating hormone (U/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers - Serum osteocalcin (ng/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>Serum osteocalcin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers - Serum N-telopeptide of type I collagen (nmol/L)</measure>
    <time_frame>1 year</time_frame>
    <description>Serum N-telopeptide of type I collagen (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Total cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Total cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Triglycerides (mg/dL)</measure>
    <time_frame>1 year</time_frame>
    <description>Triglycerides (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Lipoprotein a (mg/dL)</measure>
    <time_frame>1 year</time_frame>
    <description>Lipoprotein a (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Fasting glucose (mg/dL)</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting glucose (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Fasting insulin (pmol/L)</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting insulin (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Homeostatic model assessment (HOMA) insulin</measure>
    <time_frame>1 year</time_frame>
    <description>Homeostatic model assessment (HOMA) insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Tissue-type plasminogen activator antigen (ng/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>Tissue-type plasminogen activator antigen (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Plasma plasminogen activator inhibitor 1 (ng/mL)</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma plasminogen activator inhibitor 1 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Fibrinogen (mg/dL)</measure>
    <time_frame>1 year</time_frame>
    <description>Fibrinogen (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - Factor VII (%)</measure>
    <time_frame>1 year</time_frame>
    <description>Factor VII (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Markers - C-reactive protein (mg/L)</measure>
    <time_frame>1 year</time_frame>
    <description>C-reactive protein (mg/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <arm_group>
    <arm_group_label>Hormone Replacement Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Oral Contraceptives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement Therapy</intervention_name>
    <description>Hormone replacement therapy as indicated in Arm 1</description>
    <arm_group_label>Hormone Replacement Therapy</arm_group_label>
    <other_name>Estradiol</other_name>
    <other_name>Prometrium</other_name>
    <other_name>Micronized progestin</other_name>
    <other_name>Medroxyprogesterone</other_name>
    <other_name>Climera</other_name>
    <other_name>Provera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Oral Contraceptives</intervention_name>
    <description>Combined oral contraceptives as indicated in Arm 2</description>
    <arm_group_label>Combined Oral Contraceptives</arm_group_label>
    <other_name>Ethinyl estradiol</other_name>
    <other_name>Norgestimate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients,

          -  Between 14-45 years of age

          -  Post-menarchal

          -  Presence of uterus

          -  POI as defined by: change in menstrual function (oligomenorrhea and/or amenorrhea),
             elevated serum serum follicle stimulating hormone (FSH), low serum estradiol
             concentrations, or estrogen deficiency symptoms.

        Exclusion Criteria:

          -  Pregnancy or lactation within previous 3 months

          -  Use of hormonal contraception or replacement within previous 3 months

          -  Any contraindication to oral contraceptive pills or hormone replacement therapy per
             the current drug labels. These could include, but are not limited to: history of
             venous thromboembolism,estrogen-sensitive cancer history, regular cigarette smoking
             and history of or active liver disease, etc.

          -  Patients will be screened for pregnancy with a urine HCG test at time of screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalie C Stentz, MD</last_name>
    <phone>215-614-1414</phone>
    <email>stentzn@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clarisa R Gracia, MD, MSCE</last_name>
    <phone>215-614-1414</phone>
    <email>cgracia@uphs.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn Fertility Care</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie C Stentz, MD</last_name>
      <phone>215-614-1414</phone>
      <email>stentzn@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Clarisa R Gracia, MD, MSCE</last_name>
      <phone>215-614-1414</phone>
      <email>cgracia@uphs.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>premature ovarian failure</keyword>
  <keyword>hormone replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Norgestimate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

